AorticLab’s Post

⚡Meet Luca Mazzei, one of our skilled biomedical engineers who joined us in 2020⚡   ⚙️ Over the years, Luca has taken on more responsibilities, but his passion for design and engineering remains at the heart of his work. He’s been a key contributor to the design of our FLOWer device, applying his problem-solving skills with precision. 📊 This year, he’s challenging himself with a statistics course, and we’re confident that his determination will lead him to new achievements. 🔦 We're proud to have someone as dedicated and versatile as Luca on our team, and we can’t wait to see what’s next for him. Keep shining, Luca! #team #AorticLab #FLOWer

🎉 We are glad to announce the opening of a new center in the Netherlands, at Maastricht UMC ! 💖 A special thank you to the entire team involved, especially to interventional cardiologist Pieter Vriesendorp and the cardiothoracic surgeon Suzanne Kats, MD, PhD, MBA for the successful use of our embolic protection device FLOWer during the TAVI procedure. The use of the filter was crucial, as it successfully blocked and captured a thrombus in its basket, which would have otherwise endangered the patient's health. 🌟 A heartfelt thanks to our new distributor Angiocare 🤝 we are truly excited about this partnership and look forward to achieving great things together!

🏥 It is with great pleasure that we announce that Ospedale San Giovanni Bosco in Turin has marked a significant achievement by performing its first TAVI procedure with FLOWer, our embolic protection device.   🙌 We wish to express our sincere gratitude to Dr. Giacomo Boccuzzi, Dr. Mario Iannaccone, Dr. Francesco Colombo and Dr. Salvatore Colangelo and the exceptional team for their outstanding expertise and commitment. We sincerely appreciate our distributor, KARDIA Srl, for the amazing collaboration.   🚀 This achievement is a testament to our commitment to technological innovation and improving patient care. We are delighted to work with so many extraordinary professionals and to make a difference in the field of cardiology.   #FLOWer #AorticLab #Healthcare #MedicalTechnology

🌟 We are happy to share that we have opened a new hospital center in Germany! Heidelberg University Hospital has successfully completed the first TAVI procedure using FLOWer, our innovative embolic protection device. 👏 A special thank you to Dr Haitham Abu Sharar MD FESC, Florian Leuschner and Lorenz Lehmann and the extraordinary team for their dedication and professionalism. We also extend our deepest gratitude to our Distributor, CoRRect Medical GmbH, for their continuous support and collaboration. 💉 This achievement represents a significant step forward in improving the safety of cardiac procedures. We are proud to collaborate with such talented professionals and to contribute to the advancement of medicine. #FLOWer #AorticLab #MedicalInnovation #Cardiology #MedicalTechnology

🌟 Ensuring Patient Safety in TAVI: A Closer Look at Periprocedural Stroke 🌟   🚨 A Message from Our Chief Scientific Officer, Enrico Pasquino 🚨   I am excited to share findings from Kapadia and Reddy on the issue of periprocedural stroke after TAVI. New studies on EPDs show promising results in protecting cerebral and peripheral organs, reducing disabling strokes during TAVI. This complication is often considered by patients to be worse than death itself. Kapadia analyzed strokes in a large USA cohort of TAVI patients undergoing ViV-TAVI procedures with or without EPDs (1,610 vs. 17,480). The rate of overall strokes was significantly higher in non-EPD patients (4.3% non-EPD vs. 2.0% EPD) as well as for major strokes (3.3% non-EPD vs. 1.7% EPD). He concluded that operators should consider utilizing EPDs for patients undergoing ViV-TAVI. By 2035, ViV-TAVI procedures will increase fivefold (8,000 in 2024 vs. 40,000 in 2035).   Reddy published, in EuroIntervention, a review of the literature on the epidemiology and mechanisms of neurological events in TAVI patients and evaluated potential preventive measures. Tables for procedural and clinical risk factors for strokes in TAVI have been identified, with significant evidence supporting the use of EPDs.   I further emphasize that, besides procedural and clinical factors, EPD design plays an important role in protecting patients during TAVI. Key factors for EPD clinical adoption include device stability, usability, full body protection with low pore size filter mesh, low intrinsic device embolic potential, and low vascular access site injuries.   📊 Key Findings • Fivefold ViV-TAVI procedures growing by 2035 •  ViV-TAVI stroke risk: 2.0% or 4.3% w/wo EPD • EPDs to be used when procedural and clinical factors are present •  Efficacy stability and easy of use as key factors for EPDs adoption   🧠 Understanding Stroke Origins Reddy highlights that acute stroke (<24 hours) is often due to embolization of valve debris or thrombus during the procedure. Captured materials like calcium, tissue, thrombus, and atheroma in EPDs offer insights into stroke prevention.   🔧 EPDs and Their Future EPDs use is increasing but not yet widespread. Evidence supports their efficacy, and ongoing trials may expand their use from capturing debris to actively preventing stroke during TAVI.   🌸 Proud Mention: FLOWer Our product, FLOWer (CE marked), is cited in Reddy’s paper among EPDs advancing patient safety during TAVI. This highlights our commitment to innovation in healthcare.   As Chief Scientific Officer at AorticLab, I believe in investing in research and technology to enhance patient safety during TAVI and other procedures at risk for ischemic stroke. Preventing stroke is crucial, and with advancements in EPDs technology, we are moving towards a safer future for patients.   Read the full papers for comprehensive insights. [Link in comments]   #TAVI #FLOWer #AorticLab #StrokePrevention #PatientSafety

🌻 Meet Giulia Parigi, one of the first people to join AorticLab 🌻   👩🏻🔬 She currently holds the position of Senior Clinical Specialist. Throughout her career, she has received several promotions within the company and is excited to witness the exponential growth AorticLab is experiencing. She is particularly satisfied with seeing the project of FLOWer start from scratch and come to completion. One of her professional goals is to carry out an FDA study and introduce a new device in the clinical field.   🗺️ Outside of work, Giulia has various interests including sports, music, and photography. The one passion she shares with her career is traveling, as her role involves frequent relocations which she finds extremely exciting.   💝 Giulia is a crucial asset to our company. Her experience and skills are highly appreciated and contribute significantly to our success. We are grateful for her dedication and look forward to the many innovations she will bring to AorticLab's future. #team #AorticLab

👋🏻 Meet Francesco Cutrona, our dedicated Controller at AorticLab. 👋🏻 ✈️ In Aorticlab, Francesco enjoys the cross-departmental interactions and the vibrant atmosphere created daily with his colleagues. Initially, he admits he was a little hesitant to transition from a larger and more structured company to a start-up. However, today he is delighted because this change has helped him grow as a person. 📈 Francesco's professional goals include learning to manage a team and improving his business management skills. 🎬 In addition to his work, Francesco has many passions. He loves cinema, diving, and theatre. Moreover, he has been volunteering with a youth association for about ten years. 💡 Francesco is a passionate individual who strives to live a life full of interests and passions. He is grateful for his career and the opportunities he has been given so far. Francesco looks forward to further growth and achieving his professional goals with commitment and determination. #Team #AorticLab